Physicians Prefer Two Drugs In A Single Pill Combination For Cardiovascular Disease

Armen Hareyan's picture

Cardiovascular Disease

Decision Resources finds that 56% of primary care physicians and 53% of cardiologists said they would like more than 2 drugs in a single pill combination.


When triple-drug single pill combinations were considered, physicians desired the combination of ACEI, beta blocker, and statin.

The report also finds that managed care organization pharmacy directors will relegate Novartis's Norvasc and Diovan combination, Exforge, to tier 3 of their formularies. Sixty-five percent of managed care organizations say they will place Exforge on tier 3, a further 20% say they will exclude the agent from their formularies.

"Tier 3 placement will result in an average patient co-payment of $37.31 in private plans, versus $20.06 for tier 2, and $8.55 for tier 1," said John Earl, Ph.D., director at Decision Resources. "One-third of managed care organizations do expect to give favorable tier status to extended release niacin and simvastatin."

Combination Cardiovascular Drugs: A Survey of PCPs, Cardiologists, and MCO Pharmacy Directors is based on a U.S. survey of 71 primary care physicians, 73 cardiologists, and 17 managed care pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.